TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Sees Large Growth in Short Interest

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) was the target of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 540,900 shares, an increase of 232.0% from the February 13th total of 162,900 shares. Based on an average trading volume of 1,740,000 shares, the short-interest ratio is currently 0.3 days. Approximately 81.8% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of TransCode Therapeutics in a research note on Thursday, February 6th.

TransCode Therapeutics Stock Performance

NASDAQ RNAZ opened at $1.02 on Thursday. TransCode Therapeutics has a 52 week low of $0.97 and a 52 week high of $66.33. The stock’s 50 day moving average price is $5.65 and its two-hundred day moving average price is $241.35.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.